Mayo Clinic Ventures pumped in a share of the proceeds for Cadence Neuroscience, which is working on biomarker-powered neuromodulation therapies for drug resistant-focal epilepsy.
US-based neuromodulation therapy developer Cadence Neuroscience has collected $15m in a series A round involving Mayo Clinic Ventures, the corporate venturing vehicle for medical research company Mayo Clinic.
The round was led by venture capital firm Jazz Venture Partners and also featured Mayo’s Benefactor Innovation Fund and nonprofit organisation Epilepsy Foundation of America.
Cadence Neuroscience is working on a neuromodulation-based treatment for patients living with focal epilepsy whose seizures do not respond to existing drug treatments.
The approach, intended for…
